Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial

Cancer Res (2018) 78 (4_Supplement): PD3-03.

DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD3-03

Published: 15 February 2018

View article

Journal Articles

Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer

M Verrill, A Wardley, J Retzler, AB Smith, D McNicol, S Dando, I Tran, I Leslie, P Schmid

Cancer Res (2018) 78 (4_Supplement): P6-12-14.

DOI: https://doi.org/10.1158/1538-7445.SABCS17-P6-12-14

Published: 15 February 2018

View article

Journal Articles

Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

N Turner, H Bye, S Kernaghan, P Proszek, C Fribbens, L Moretti, J Morden, C Snowdon, I Macpherson, A Wardley, R Roylance, R Baird, J Bliss, A Ring

Cancer Res (2018) 78 (4_Supplement): OT1-06-03.

DOI: https://doi.org/10.1158/1538-7445.SABCS17-OT1-06-03

Published: 15 February 2018

View article

Journal Articles

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

I Krop, J Cortes, K Miller, MT Huizing, L Provencher, L Gianni, S Chan, M Trudeau, J Steinberg, J Sugg, M Liosatos, VE Paton, A Peterson, A Wardley

Cancer Res (2017) 77 (4_Supplement): P4-22-08.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-22-08

Published: 15 February 2017

View article

Journal Articles

Abstract S6-01: BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Cancer Res (2017) 77 (4_Supplement): S6-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-S6-01

Published: 15 February 2017

View article

Journal Articles

Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse.

JM Bliss, P Ellis, L Kilburn, J Bartlett, D Bloomfield, D Cameron, P Canney, RE Coleman, M Dowsett, H Earl, M Verril, A Wardley, J Yarnold, R Ahern, N Atkins, M Fletcher, M McLinden, P Barrett-Lee

Cancer Res (2012) 72 (24_Supplement): P1-13-03.

DOI: https://doi.org/10.1158/0008-5472.SABCS12-P1-13-03

Published: 15 December 2012

View article

Journal Articles

Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)

Cancer Res (2012) 72 (24_Supplement): S3-3.

DOI: https://doi.org/10.1158/0008-5472.SABCS12-S3-3

Published: 15 December 2012

View article

Journal Articles

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

L Gianni, G Romieu, M Lichinitser, S Serrano, M Mansutti, X Pivot, I Smirnova, A Moliterni, F Andre, A Chan, O Lipatov, S Chan, A Wardley, R Greil, L Provencher, N Moore, S Prot, V Semiglazov

Cancer Res (2011) 71 (24_Supplement): S4-8.

DOI: https://doi.org/10.1158/0008-5472.SABCS11-S4-8

Published: 15 December 2011

View article

Journal Articles

Abstract P5-10-06: TACT2 Randomised Adjuvant Trial in Early Breast Cancer (EBC): Tolerability and Toxicity of Standard 3 Weekly Epirubicin (E) Versus Accelerated Epirubicin (aE) in 129 UK Hospitals (4391 Patients) (CRUK/05/019)

D Cameron, P Barrett-Lee, G Velikova, P Canney, H Moyses, M McDermaid, J Banerji, C Gaunt, C Reynolds, A Wardley, A Bowman, G Bertelli, N Murray, JM Bliss

Cancer Res (2010) 70 (24_Supplement): P5-10-06.

DOI: https://doi.org/10.1158/0008-5472.SABCS10-P5-10-06

Published: 15 December 2010

View article

Journal Articles

Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer

Cancer Res (2010) 70 (24_Supplement): S4-3.

DOI: https://doi.org/10.1158/0008-5472.SABCS10-S4-3

Published: 15 December 2010

View article

Journal Articles

Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial.

M. Regan, M. Colleoni, A. Giobbie-Hurder, B. Thuerlimann, H. Mouridsen, L. Mauriac, R. Paridaens, J. Forbes, A. Wardley, I. Smith, K. Price, A. Goldhirsch, A. Coates, R. Gelber

Cancer Res (2009) 69 (24_Supplement): 16.

DOI: https://doi.org/10.1158/0008-5472.SABCS-09-16

Published: 15 December 2009

View article

Journal Articles

Preliminary Phase II Data Suggest That Entinostat (SNDX275), a Class 1 Selective Histone Deacetylase Inhibitor (HDACi), May Resensitize Breast Cancer Patients Progressing on Aromataste Inhibitor (AI) Therapy to Their AI Therapy.

A. Wardley, J. McCaffrey, J. Crown, R. Stein, Z. Malik, D. Rea, P. Barrett-Lee, G. Lee

Cancer Res (2009) 69 (24_Supplement): 6111.

DOI: https://doi.org/10.1158/0008-5472.SABCS-09-6111

Published: 15 December 2009

View article

Journal Articles

Phase I Trial of Panobinostat (LBH589) in Combination with Trastuzumab in Pretreated HER2-Positive Metastatic Breast Cancer (mBC): Preliminary Safety, Efficacy and Pharmacokinetic Results.

M. Campone, P. Conte, D. Amadori, P. Pronzato, A. Wardley, K. McBride, A. Fandi

Cancer Res (2009) 69 (24_Supplement): 6101.

DOI: https://doi.org/10.1158/0008-5472.SABCS-09-6101

Published: 15 December 2009

View article

Journal Articles

Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC).

A Wardley, C Lohrisch, A Joy, S Young, F Yi, A Marme, L Dreosti, J Albanell, M Muñoz, DW Miles

Cancer Res (2009) 69 (2_Supplement): 1035.

DOI: https://doi.org/10.1158/0008-5472.SABCS-1035

Published: 15 January 2009

View article

Journal Articles

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

HT Mouridsen, A Giobbie-Hurder, L Mauriac, R Paridaens, M Colleoni, B Thuerlimann, JF Forbes, RD Gelber, A Wardley, I Smith, KN Price, A Coates, A Goldhirsch, BIG I-98 Collaborative and the International Breast Cancer Study Group

Cancer Res (2009) 69 (2_Supplement): 13.

DOI: https://doi.org/10.1158/0008-5472.SABCS-13

Published: 15 January 2009

View article

NARROW

Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial

Abstract P6-12-14: Quality of life and ability to work in patients at different disease stages of HER2+ breast cancer

Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

Abstract S6-01: BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse.

Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

Abstract P5-10-06: TACT2 Randomised Adjuvant Trial in Early Breast Cancer (EBC): Tolerability and Toxicity of Standard 3 Weekly Epirubicin (E) Versus Accelerated Epirubicin (aE) in 129 UK Hospitals (4391 Patients) (CRUK/05/019)

Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer

Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial.

Preliminary Phase II Data Suggest That Entinostat (SNDX275), a Class 1 Selective Histone Deacetylase Inhibitor (HDACi), May Resensitize Breast Cancer Patients Progressing on Aromataste Inhibitor (AI) Therapy to Their AI Therapy.

Phase I Trial of Panobinostat (LBH589) in Combination with Trastuzumab in Pretreated HER2-Positive Metastatic Breast Cancer (mBC): Preliminary Safety, Efficacy and Pharmacokinetic Results.

Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC).

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only